The EMA has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer trial in Europe to add 11 new sites.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Imvax has secured $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of IGV-001, in ndGBM individuals.

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

The US Food and Drug Administration has released draft guidance on protocol deviations, but experts say it could go further.

The trial combines tislelizumab and Anktiva for treating advanced or metastatic non-small cell lung cancer patients. Credit: NMK-Studio/Shutterstock. ImmunityBio has entered a supply agreement and ...

The potential secretary for Health and Human Services has been forced to defend his previous anti-vaccine stances at his ...